RYZOLT
Clinical safety rating
cautionComprehensive clinical and safety monograph for RYZOLT (RYZOLT).
RYZOLT is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, increasing serotonin levels in the synaptic cleft.
| Metabolism | Primarily metabolized by CYP2D6 and CYP2C19 to active metabolite norfluoxetine. Inhibits CYP2D6, leading to potential drug interactions. |
| Excretion | Primarily hepatic metabolism with renal excretion of metabolites; renal elimination of unchanged drug <5%; biliary excretion accounts for ~10% of total clearance. |
| Half-life | Terminal elimination half-life is 12–15 hours in healthy adults; extended to 22–28 hours in patients with severe hepatic impairment. |
| Protein binding | 98% bound primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.8–1.2 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral: 45–55% due to first-pass metabolism; Intravenous: 100%. |
| Onset of Action | Oral: 30–60 minutes; Intravenous: 2–5 minutes. |
| Duration of Action | Oral: 8–12 hours; Intravenous: 4–6 hours. Duration increased in hepatic impairment. |
| Molecular Weight | Tramadol HCl: 299.84 Da (base 263.38); Celecoxib: 381.37 Da |
10 mg orally once daily
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | GFR 30-89 mL/min: no adjustment; GFR 15-29 mL/min: 5 mg once daily; GFR <15 mL/min: not recommended |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 5 mg once daily; Child-Pugh C: not recommended |
| Pediatric use | 0.2 mg/kg (max 10 mg) orally once daily for weight ≥10 kg |
| Geriatric use | No initial dose adjustment required, but monitor renal function and titrate cautiously |
| 1st trimester | Ryzolt is a combination of tramadol and celecoxib; use in first trimester is not recommended due to potential teratogenic effects (tramadol: neural tube defects; celecoxib: cardiovascular defects) and lack of adequate safety data. |
| 2nd trimester | Use in second trimester only if clearly needed; celecoxib may cause premature closure of ductus arteriosus after 30 weeks, but risk is lower in mid-pregnancy. Tramadol may cause withdrawal in neonate. |
| 3rd trimester | Avoid in third trimester; celecoxib is contraindicated after 30 weeks due to risk of premature ductus arteriosus closure; tramadol may cause neonatal withdrawal syndrome and respiratory depression. |
Clinical note
Comprehensive clinical and safety monograph for RYZOLT (RYZOLT).
| Placental transfer | Both components cross the placenta. Tramadol and its active metabolite (M1) transfer readily, with fetal concentrations similar to maternal. Celecoxib also crosses the placenta, with fetal levels approximately 30% of maternal levels. Evidence from animal studies and human clinical data confirms significant placental transfer. |
| Breastfeeding | Tramadol and its active metabolite are excreted into breast milk; in nursing infants, tramadol can cause sedation, respiratory depression, and withdrawal symptoms. Celecoxib is excreted in low concentrations but may cause adverse effects in infants. Breastfeeding is not recommended during Ryzolt therapy. If unavoidable, monitor infant for drowsiness, poor feeding, and respiratory distress. |
| Lactation Rating | L5 (Avoid) – contraindicated due to potential for serious adverse reactions in nursing infants. |
| Teratogenic Risk | First trimester: Increased risk of major congenital malformations (cardiac, neural tube defects) based on animal studies and limited human data. Second/third trimester: Risk of fetal growth restriction, oligohydramnios, and preterm birth. Use only if benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal blood pressure, renal function, and electrolytes monthly. Perform serial fetal ultrasound for growth and amniotic fluid volume every 4 weeks starting at 24 weeks. Fetal heart rate monitoring non-stress test weekly after 32 weeks. |
| Fertility Effects | Reversible impaired spermatogenesis in males; oligomenorrhea and anovulation in females. Effects on fertility return to baseline after discontinuation. |
■ FDA Black Box Warning
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants. Close monitoring for clinical worsening, suicidality, and unusual changes in behavior is advised.
| Serious Effects |
Hypersensitivity to tramadol, celecoxib, sulfonamides (celecoxib is a sulfonamide), or any component of the formulationAsthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDsCoronary artery bypass graft (CABG) surgery (perioperative pain)History of serious cardiovascular thrombotic events (e.g., myocardial infarction, stroke) or established cardiovascular diseaseSignificant gastrointestinal bleeding, ulceration, or perforationChronic opioid use disorders or concurrent use of MAO inhibitors (tramadol component)Severe hepatic impairment (Child-Pugh class C) or active liver diseaseSevere renal impairment (CrCl <30 mL/min) or dialysisThird trimester pregnancy (after 30 weeks gestation)Lactation (breastfeeding)
| Precautions | Serotonin syndrome, activation of mania/hypomania, hyponatremia, QT prolongation, increased risk of bleeding, angle-closure glaucoma, and discontinuation syndrome upon abrupt withdrawal. |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they may increase drug levels. No other significant food interactions. Can be taken with or without food. |
| Clinical Pearls | RYZOLT (isavuconazonium) is a prodrug of isavuconazole, a triazole antifungal. Monitor liver function tests due to hepatotoxicity risk. Adjust dose in hepatic impairment (Child-Pugh B: reduce dose; Child-Pugh C: not recommended). QT prolongation possible; avoid with strong CYP3A4 inducers/inhibitors. Therapeutic drug monitoring not routinely required. |
| Patient Advice | Take with or without food; avoid grapefruit products. · Do not drive or operate machinery if you experience dizziness or confusion. · Complete full course even if feeling better. · Report immediately: yellowing skin/eyes, dark urine, severe fatigue, signs of allergic reaction. · Use effective contraception; may cause fetal harm. |
Loading safety data…